EPA:DIM Sartorius Stedim Biotech (DIM) Stock Price, News & Analysis €184.80 -2.20 (-1.18%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range€184.30▼€189.1050-Day Range€145.35▼€189.7552-Week Range N/AVolume75,017 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Sartorius Stedim Biotech alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Sartorius Stedim Biotech Stock (EPA:DIM)Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.Read More DIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DIM Stock News HeadlinesSeptember 16 at 5:54 AM | sg.finance.yahoo.comSartorius Stedim Biotech S.A. (56S1.DE)September 9, 2024 | msn.comFrance shares mixed at close of trade; CAC 40 up 0.99%September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.September 7, 2024 | msn.comFrance shares lower at close of trade; CAC 40 down 1.07%September 6, 2024 | markets.businessinsider.comKepler Capital Sticks to Its Sell Rating for Sartorius (0NIR)September 6, 2024 | markets.businessinsider.comKepler Capital Sticks to Their Hold Rating for Sartorius Stedim Biotech (0RG8)September 2, 2024 | markets.businessinsider.comRBC Capital downgrades Sartorius (0NIR) to a HoldAugust 27, 2024 | msn.comFrance shares mixed at close of trade; CAC 40 down 0.32%September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 16, 2024 | finance.yahoo.comSartorius Stedim Biotech S.A. (DIMP.XC)August 14, 2024 | uk.investing.comBlackRock Greater Europe Investment Trust: High-Quality Fund in Underappreciated RegionAugust 14, 2024 | finance.yahoo.comViroCell Biologics Completes Oversubscribed FinancingAugust 13, 2024 | finance.yahoo.comSartorius Stedim Biotech S.A. (SRTOY)August 1, 2024 | seekingalpha.comSRTOY Sartorius Stedim Biotech S.A.July 29, 2024 | markets.businessinsider.comSartorius (0NIR) Receives a Buy from J.P. MorganJuly 26, 2024 | uk.finance.yahoo.comSartorius Stedim Biotech S.A. (DIM.VI)July 20, 2024 | seekingalpha.comSartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call TranscriptJuly 19, 2024 | finanznachrichten.deSartorius Stedim Biotech SA: Half-year results 2024 of SartoriusStedimBiotech -2-See More Headlines Receive DIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeEPA SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolEPA:DIM CUSIPN/A CIKN/A Webwww.sartorius.com Phone33 4 42 84 56 00FaxN/AEmployees10,493Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Rene Faber (Age 49)CEO & DIrector Comp: $540kMr. Rainer Lehmann (Age 49)CFO & Member of Executive Board Ms. Petra MullerHead of Investor RelationsMs. Petra Kirchhoff (Age 55)Head of Corporate Communications & IR Olivier GuitardHead of Controlling BPSKey CompetitorsEssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIESartorius AktiengesellschaftFRA:SRT3Sartorius AktiengesellschaftETR:SRTCarl Zeiss MeditecETR:AFXView All Competitors DIM Stock Analysis - Frequently Asked Questions How have DIM shares performed this year? Sartorius Stedim Biotech's stock was trading at €239.50 at the beginning of 2024. Since then, DIM stock has decreased by 22.8% and is now trading at €184.80. View the best growth stocks for 2024 here. What other stocks do shareholders of Sartorius Stedim Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sartorius Stedim Biotech investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and This page (EPA:DIM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sartorius Stedim Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DIM Stock Alerts